GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyundai Bioscience Co Ltd (XKRX:048410) » Definitions » Cyclically Adjusted Revenue per Share

Hyundai Bioscience Co (XKRX:048410) Cyclically Adjusted Revenue per Share : ₩707.29 (As of Mar. 2025)


View and export this data going back to 2002. Start your Free Trial

What is Hyundai Bioscience Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Hyundai Bioscience Co's adjusted revenue per share for the three months ended in Mar. 2025 was ₩16.165. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₩707.29 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Hyundai Bioscience Co's average Cyclically Adjusted Revenue Growth Rate was -10.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -9.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -19.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Hyundai Bioscience Co was -9.40% per year. The lowest was -36.60% per year. And the median was -29.40% per year.

As of today (2025-05-31), Hyundai Bioscience Co's current stock price is ₩11060.00. Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ₩707.29. Hyundai Bioscience Co's Cyclically Adjusted PS Ratio of today is 15.64.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hyundai Bioscience Co was 44.29. The lowest was 0.41. And the median was 16.00.


Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Chart

Hyundai Bioscience Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,399.43 993.18 857.18 797.11 737.96

Hyundai Bioscience Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 788.96 788.62 770.49 737.96 707.29

Competitive Comparison of Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Hyundai Bioscience Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hyundai Bioscience Co's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hyundai Bioscience Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Hyundai Bioscience Co's Cyclically Adjusted PS Ratio falls into.


;
;

Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hyundai Bioscience Co's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=16.165/122.5900*122.5900
=16.165

Current CPI (Mar. 2025) = 122.5900.

Hyundai Bioscience Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 422.770 100.051 518.011
201509 232.698 100.111 284.949
201512 240.655 100.220 294.370
201603 313.218 100.561 381.832
201606 223.009 100.791 271.242
201609 260.179 101.461 314.360
201612 338.529 101.561 408.623
201703 186.204 102.851 221.941
201706 182.367 102.611 217.874
201709 228.832 103.491 271.064
201712 345.182 102.991 410.870
201803 187.074 104.101 220.300
201806 290.966 104.130 342.547
201809 235.057 105.651 272.745
201812 198.445 104.351 233.131
201903 211.532 104.491 248.172
201906 219.184 104.881 256.193
201909 182.666 105.200 212.861
201912 205.511 105.121 239.662
202003 110.133 105.354 128.151
202006 88.314 105.112 102.999
202009 77.898 106.198 89.922
202012 51.277 105.765 59.434
202103 51.094 107.357 58.344
202106 59.857 107.579 68.209
202109 47.406 108.759 53.435
202112 61.371 109.676 68.597
202203 56.822 111.848 62.279
202206 33.679 114.072 36.194
202209 56.815 114.715 60.715
202212 40.544 115.179 43.153
202303 75.237 116.507 79.165
202306 76.561 117.182 80.094
202309 46.683 118.964 48.106
202312 27.086 118.837 27.941
202403 120.299 120.123 122.769
202406 219.270 120.007 223.989
202409 10.863 120.861 11.018
202412 11.368 121.135 11.505
202503 16.165 122.590 16.165

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Hyundai Bioscience Co  (XKRX:048410) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Hyundai Bioscience Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=11060.00/707.29
=15.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Hyundai Bioscience Co was 44.29. The lowest was 0.41. And the median was 16.00.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Hyundai Bioscience Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Hyundai Bioscience Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Hyundai Bioscience Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
150 North-Ahyun Road, 3rd Floor Academic Cooperation Building, Ehwa Women’s University, Seodaemun-gu, Seoul, KOR
Hyundai Bioscience Co Ltd is a Korean biotechnology company. The company is engaged in developing and commercializing bio-fusion technology with the purpose of delivering active ingredients safely and efficiently to the body. It has developed Vitabrid CG, a biomaterial that binds vitamin C with bio-friendly mineral layers, which is a beneficial ingredient in skin brightening, anti-aging, and anti-inflammation; and Vitabrid C12, a premium skincare brand.

Hyundai Bioscience Co Headlines

No Headlines